Enavogliflozin (Synonyms: DWP-16001) |
| カタログ番号GC64266 |
抗糖尿病薬であるエナボグリフロジン (DWP-16001) は、経口活性でクラス最高の選択的ナトリウム-グルコース共輸送体-2 (SGLT-2) 阻害剤です 。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1415472-28-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
[1]. Daewoong speeds up developing antidiabetic Enavogliflozin
[2]. These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin
[3]. Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong’s Enavogliflozin & Janssen Biotech’s Golimumab Among Others - ResearchAndMarkets.com
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *